Anteris Technologies Ltd (ASX:AVR) has changed its name from Admedus Ltd (ASX:AHZ) following shareholder approval at the company's annual general meeting this month.
Anteris is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients.
Its focus is on developing next-generation technologies with world-class partners.
Durable heart valve with ADAPT®[hhmc]
Competing in a potential US$8 billion market, the company is developing the worlds most durable heart valve with its ADAPT® anti-calcification treatment platform technology.
ADAPT® has unique properties that are critical to longer-lasting aortic valves and has been used in more than 20,000 patients globally.
DurAVR
, built with ADAPT® technology, is a novel and highly durable 3D single-piece aortic valve for the treatment of aortic stenosis.
DurAVR also has unique properties that are critical to longer-lasting valves and is now in human clinical trials following successful preclinical studies.
Anti-calcification comparison[hhmc]
After successfully enrolling and discharging its first patient in a first in human DurAVR SAVR Feasibility Clinical Study in April, the company has been progressing with preclinical animal studies.
A preclinical study is underway to compare anti-calcification properties of its proprietary ADAPT® treated tissue with other bovine and porciRead More – Source
[contf]
[contfnew]
Proactiveinvestors
[contfnewc]
[contfnewc]
